Patent · US Active

FcRn antagonists and methods of use

US11505585B2 · kind B2 · utility

4Cited by

35References

10Claims

0Family size

Assignees

argenx BV · BE
The Board of Regents of the University of Texas System · US

Inventors

Peter Ulrichts · Breda, NL
Christophe Blanchetot · Laarne, BE
Torsten Dreier · Breda, NL
Johannes Joseph Wilhelmus De Haard · Vlaardingen, NL
E. Sally Ward Ober · College Station, US
Nicolas Ongenae · Wondelgem, BE

Key dates

Filing date	Nov 22, 2017
Grant date	Nov 22, 2022
Priority date	—
Expiry date	Jan 8, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.